EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways

Hany M Fayed, Gihan F Asaad, Marawan A Elbaset, Ola A Sharaf, Sawsan S Mahmoud, Mohamed M Amin, Zeinab A El-Gendy, Fatma A Ibrahim, Sherein S Abdelgayed, Rehab F Abdel-Rahman

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-11 · 398 (11) · 16131-16148

DOI: 10.1007/s00210-025-04098-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 29.05.2025. Verfasst von Hany M Fayed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt. Hauptthemen laut MEDLINE: Canagliflozin, Carcinoma, Hepatocellular, Sodium-Glucose Transporter 2 Inhibitors, Liver Neoplasms, Experimental. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Centre Egypt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer. Many medications that had been used for a long period to treat the illness were eventually stopped due to negative effects or the development of drug resistance in HCC patients. Canagliflozin (CANA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, showed in vitro anti-carcinogenic efficacy against various cancer models’ other livers. The current study used rat models to examine canagliflozin’s therapeutic role against experimentally induced HCC. A total of 32 rats were divided into four groups, eight in each: negative control; HCC control: rats were fed a choline-deficient diet (CDD) and subjected to diethyl nitrosamine and thioacetamide (DEN/TAA) injections for 15 weeks; and treated groups: rats were given CANA (10 and 20 mg/kg b.wt.) orally from the 7th week of the experiment till the end. All the measured markers of HCC, liver function, and inflammatory markers were elevated in the HCC control group compared to the negative control (CTRL). Regarding immunohistochemistry, the HCC group showed downregulation in caspase-3 expression and upregulation in PCNA expression. On the other hand, canagliflozin-treated groups showed dose-dependent improvement in the measured parameters associated with HCC. Moreover, canagliflozin therapy ameliorates the histopathological alterations in HCC-induced rats. Taken together, CANA exhibits anti-HCC effects by activating AMP-activated protein kinase (AMPK) and suppressing the HIF-1α/YAP/TAZ pathway, making it a forthcoming therapeutic option for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinCarcinoma, HepatocellularSodium-Glucose Transporter 2 InhibitorsLiver Neoplasms, ExperimentalAnimalsAMP-Activated Protein KinasesHypoxia-Inducible Factor 1, alpha SubunitMaleSignal TransductionDiethylnitrosamineYAP-Signaling ProteinsThioacetamideRatsCholine DeficiencyTranscription FactorsLiverRats, Sprague-Dawley

Stichwörter der Autor:innen

CanagliflozinDiethyl nitrosamineHepatocellular carcinomaThioacetamide

Substanzen

CanagliflozinAMP-Activated Protein KinasesHypoxia-Inducible Factor 1, alpha SubunitDiethylnitrosamineSodium-Glucose Transporter 2 InhibitorsHif1a protein, ratYAP-Signaling ProteinsThioacetamideTranscription Factors

Autor:innen und Institutionen

  • Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
  • Biochemistry Department, Biotechnology Research Institute, National Research Centre, Giza, Egypt.
  • Department of Pathobiology, College of Veterinary Medicine, Tuskegee University, Tuskegee, AL, 36088, USA.
  • Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt.
  • Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt. rehabs2001@yahoo.com.

Förderung

  • National Research Centre Egypt

Zitieren

APA

Fayed, H. M., Asaad, G. F., Elbaset, M. A., Sharaf, O. A., Mahmoud, S. S., Amin, M. M., El-Gendy, Z. A., Ibrahim, F. A., Abdelgayed, S. S., & Abdel-Rahman, R. F. (2025). Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(11), 16131-16148. https://doi.org/10.1007/s00210-025-04098-8

Vancouver

Fayed HM, Asaad GF, Elbaset MA, Sharaf OA, Mahmoud SS, Amin MM, et al. Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(11):16131-16148. doi:10.1007/s00210-025-04098-8

BibTeX
@article{Fayed2025,
  author = {Fayed, Hany M and Asaad, Gihan F and Elbaset, Marawan A and Sharaf, Ola A and Mahmoud, Sawsan S and Amin, Mohamed M and El-Gendy, Zeinab A and Ibrahim, Fatma A and Abdelgayed, Sherein S and Abdel-Rahman, Rehab F},
  title = {Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD/DEN/TAA in a rat model: regulation of AMPK/HIF-1α/YAP-1/TAZ signaling pathways},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  volume = {398},
  number = {11},
  pages = {16131--16148},
  doi = {10.1007/s00210-025-04098-8}
}
Kostenlos starten →